AMGN · News · 20260807N
Revenue Performance and Mix
AMGEN INC · 2026-08-07 · Importance 38 · Surprise 40 · No source text
Amgen’s second-quarter 2026 revenue increased 10% year over year to $10.05 billion. Six key growth drivers increased 26% year over year and contributed nearly 70% of product sales. Twenty-two products delivered double-digit sales growth, including Repatha at $953 million, up 8.8% sequentially, and Tezspire at $486 million, up 42.1% year over year. Growth in Repatha, Evenity, Uplizna, Tezspire, and Imdelltra offset biosimilar pressure on Prolia and XGEVA.
Key facts
- Amgen reported Tezspire sales of $486 million in Q2 2026, up 42.1% year-over-year. source
- Amgen reported Repatha revenue of $953 million in Q2 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +1.4% | Amgen reported Tezspire sales of $486 million in Q2 2026, up 42.1% year-over-year. |